{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:01:24Z","timestamp":1773313284384,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ijantimicag.2013.12.008","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T19:15:57Z","timestamp":1389035757000},"page":"236-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth"],"prefix":"10.1016","volume":"43","author":[{"given":"Aikaterini","family":"Pistiki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Galani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouel","family":"Pyleris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Barbatzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0005","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Small intestinal bacterial overgrowth in patients with irritable bowel syndrome","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/MCG.0b013e3181ef3476","article-title":"Irritable bowel syndrome and small intestinal bacterial overgrowth","volume":"44","author":"Yamini","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","article-title":"The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome","volume":"57","author":"Pyleris","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOG.0b013e328333dc8d","article-title":"Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases","volume":"26","author":"Koo","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpinato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","article-title":"Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months","volume":"36","author":"Meyrat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0040","series-title":"Clinical breakpoints v. 3.1. EUCAST","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2013"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0045","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/AAC.00161-10","article-title":"Bile acids improve the antimicrobial effect of rifaximin","volume":"54","author":"Darkoh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0050","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/AAC.00739-10","article-title":"In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008","volume":"55","author":"Ouyang-Latimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0055","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/AAC.01108-07","article-title":"Systemic pharmacokinetics of rifaximin in volunteers with shigellosis","volume":"52","author":"Taylor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.45.2.643-644.2001","article-title":"In vitro activity of rifaximin against enteropathogens producing traveler\u2019s diarrhea","volume":"45","author":"Sierra","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0090","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jac\/47.6.904","article-title":"In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania","volume":"47","author":"Sierra","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.12.008_bib0095","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1128\/AAC.45.1.212-216.2001","article-title":"In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler\u2019s diarrhea in four geographic regions","volume":"45","author":"Gomi","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T16:28:48Z","timestamp":1538929728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0924857913004123"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.12.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}